Health ❯Obesity

Weight Loss Treatments

GLP-1 Agonists GLP-1 Drugs Pharmaceuticals GLP-1 Receptor Agonists Wegovy Clinical Research Medications Drug Efficacy GLP-1 Hormones Anti-Obesity Drugs Pharmaceutical Products Pharmaceutical Interventions Clinical Trials Zepbound Prescription Drugs

Novo Nordisk CEO Steps Down Following Share Price Collapse

Lars Fruergaard Jørgensen will remain temporarily to ensure a smooth transition as the company faces intensified competition and market pressures.

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

Study Highlights Benefits and Risks of Popular Weight-Loss Drugs

UK Approves Wegovy for Reducing Heart Risks in Overweight Patients

Ozempic's Expanding Role: Beyond Diabetes and Weight Loss